G Gentile1, M Andreoni2, G Antonelli3, L Sarmati4. 1. Department of Cellular Biotechnologies and Haematology, La Sapienza University, Rome, Italy. 2. Clinical Infectious Diseases, Department of System Medicine, Tor Vergata University, Rome, Italy. 3. Department of Molecular Medicine, La Sapienza University, Rome, Italy. 4. Clinical Infectious Diseases, Department of System Medicine, Tor Vergata University, Rome, Italy. Electronic address: sarmati@med.uniroma2.it.
Abstract
BACKGROUND: The growth of new therapeutic options and practices increases the risk of hepatitis B virus (HBV) reactivation in patients with haematologic malignancies and/or patients undergoing haematologic stem cell transplantation (HSCT). OBJECTIVES: To provide a systematic review supporting recommendations for prevention, monitoring, prophylaxis and therapy of HBV reactivation in patients with haematologic malignancies and HSCT. DATA SOURCES: The systematic review was based on a strategy using PubMed and the Cochrane Library searching literature published from 1991 to December 31, 2016. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) guidelines were followed. SELECTION CRITERIA: Randomized control trials, prospective and retrospective cohort studies. RISK-OF-BIAS ASSESSMENT: Cochrane Risk of Bias Tool and Newcastle Ottawa Quality Assessment Scale. RESULTS: Forty-two studies of fair or good quality were included in this systematic review. The following main results were obtained: haematologic patients should be screened for HBV before chemotherapy; HBV DNA levels should be monthly monitored in all HBV-positive patients not receiving prophylaxis; hepatitis B surface antigen (HBsAg)-positive haematologic patients and patients undergoing HSCT should receive prophylaxis and third-generation HBV drugs should be provided; and anti-hepatitis B core protein-positive lymphoma patients and patients who underwent HSCT should receive antiviral prophylaxis. CONCLUSIONS: A higher quality of evidence is needed. However, the level of evidence was sufficient to support the recommendations published in this issue of the journal.
BACKGROUND: The growth of new therapeutic options and practices increases the risk of hepatitis B virus (HBV) reactivation in patients with haematologic malignancies and/or patients undergoing haematologic stem cell transplantation (HSCT). OBJECTIVES: To provide a systematic review supporting recommendations for prevention, monitoring, prophylaxis and therapy of HBV reactivation in patients with haematologic malignancies and HSCT. DATA SOURCES: The systematic review was based on a strategy using PubMed and the Cochrane Library searching literature published from 1991 to December 31, 2016. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) guidelines were followed. SELECTION CRITERIA: Randomized control trials, prospective and retrospective cohort studies. RISK-OF-BIAS ASSESSMENT: Cochrane Risk of Bias Tool and Newcastle Ottawa Quality Assessment Scale. RESULTS: Forty-two studies of fair or good quality were included in this systematic review. The following main results were obtained: haematologic patients should be screened for HBV before chemotherapy; HBV DNA levels should be monthly monitored in all HBV-positive patients not receiving prophylaxis; hepatitis B surface antigen (HBsAg)-positive haematologic patients and patients undergoing HSCT should receive prophylaxis and third-generation HBV drugs should be provided; and anti-hepatitis B core protein-positive lymphomapatients and patients who underwent HSCT should receive antiviral prophylaxis. CONCLUSIONS: A higher quality of evidence is needed. However, the level of evidence was sufficient to support the recommendations published in this issue of the journal.
Authors: Ibai Los-Arcos; Gloria Iacoboni; Manuela Aguilar-Guisado; Laia Alsina-Manrique; Cristina Díaz de Heredia; Claudia Fortuny-Guasch; Irene García-Cadenas; Carolina García-Vidal; Marta González-Vicent; Rafael Hernani; Mi Kwon; Marina Machado; Xavier Martínez-Gómez; Valentín Ortiz Maldonado; Carolina Pinto Pla; José Luis Piñana; Virginia Pomar; Juan Luis Reguera-Ortega; Miguel Salavert; Pere Soler-Palacín; Lourdes Vázquez-López; Pere Barba; Isabel Ruiz-Camps Journal: Infection Date: 2020-09-26 Impact factor: 7.455